This technology is a monoclonal antibody which binds annexin for the inhibition of Funsobacterium nucleatum (Fn) invasion and proliferation to treat and prevent Fn related diseases including ...
This technology identifies both a biomarker for autoimmune hemolytic anemia (AIHA) and a potential treatment that can prevent AIHA onset (i.e., prophylactic) and mitigate disease symptoms (i.e., ...
This technology is an enzyme that is involved in synthesizing a precursor to bis(monoacylglycero)phosphate (BMP) and can be used to modulate BMP levels and treat BMP-related disorders.
This technology is a targeted anti-tumor agent designed to treat adenoid cystic carcinoma (ACC) by utilizing retinoid receptor modulation to promote cancer cell differentiation and selective cell ...
This technology identifies proteasome inhibitors and PI3K/mTOR inhibitors as therapeutic interventions for patients with pathologic vascular malformations.
This technology is a knock-in mouse model with a mutated ryanodine receptor to study catecholaminergic polymorphic ventricular tachycardia (CPVT) and other arrhythmias.
This technology is a naturally occurring non-coding RNA that regulates the SLC2A1 gene, allowing for therapeutic regulation of Glut1 for treatment of diseases in which Glut1 is under-expressed.
